| Sherwin Sattarzadeh |
Sherwin Sattarzadeh is currently working as the Chief Of Staff & Senior VP-Strategic Operations at Blueprint Medicines Corp. He previously worked at Genzyme Corp. as the Director-Regulatory Affairs from 2005 to 2015. Mr. Sattarzadeh has an undergraduate degree from the University of British Columbia and an MBA from Boston University. |
| Michael Landsittel |
Michael Landsittel is currently the Chief Financial Officer at Blueprint Medicines Corp. He previously worked as the Finance Director at Infinity Pharmaceuticals, Inc. in 2012 and as the Senior Director-Finance at Algeta US LLC from 2012 to 2014. Michael obtained his undergraduate degree from the University of Michigan in 1994 and an MBA from the Tuck School of Business at Dartmouth in 2002. |
| Tracey L. McCain |
Tracey L. McCain is an Independent Director at Kiniksa Pharmaceuticals Ltd. and Secretary, Chief Legal & Compliance Officer at Blueprint Medicines Corp. She was previously a General Counsel at Genzyme Corp. and a Senior Vice President & Head-Legal at Genzyme Therapeutics Ltd. She also worked as an Associate at Palmer & Dodge LLP. McCain received her undergraduate degree from the University of Pennsylvania and her graduate degree from Columbia Law School. |
| Christopher K. Murray |
Christopher K. Murray is currently the Chief Technical Operations & Quality Officer at Blueprint Medicines Corp. Prior to this, he worked at ARIAD Pharmaceuticals, Inc. for 13 years, where he held the position of Vice President-Technical Operations from 2013 to 2017. Murray received his undergraduate degree from Hope College in 1984 and his graduate degree from The University of Chicago in 1990. |
| Christina Rossi |
Christina Rossi is an Independent Director at Xilio Therapeutics, Inc. since 2021. She is also the Chief Operating Officer at Blueprint Medicines Corp. since 2018. Previously, she worked at Genzyme Corp. from 2012 to 2018 as the Head-Multiple Sclerosis Business Unit. Prior to that, she was the Head-Commercial Strategy at Eidetica Biopharma GmbH from 2005 to 2010. Ms. Rossi completed her undergraduate degree at Duke University in 1997 and obtained an MBA from Harvard Business School in 2003. |
| Ariel Hurley |
Ariel Hurley is currently working as the Vice President-Finance & Controller at Blueprint Medicines Corp. Ms. Hurley completed their undergraduate degree at Providence College. |
| Bumpus Durso |
Bumpus Durso is currently the Director at the Massachusetts Biotechnology Education Foundation since 2014. Additionally, Ms. Durso holds the position of Chief People Officer at Blueprint Medicines Corp. since 2015. Previously, Ms. Durso worked as the Head-Human Resources at Cubist Pharmaceuticals LLC from 2009 to 2015 and as the North American Manager at Holcim (US), Inc. from 2005 to 2009. Ms. Durso obtained an undergraduate degree from Bentley University. |
| Percy H. Carter |
Percy H. Carter is currently the Chief Scientific Officer at Blueprint Medicines Corp. Prior to this, he was the Chief Scientific Officer at FibroGen, Inc. from 2020 to 2021. He also served as the Senior Vice President & Head-Discovery at Bristol Myers Squibb Co. and Global Head-Discovery Sciences at Janssen Research & Development LLC. Carter received his undergraduate degree from Dartmouth College, his doctorate from Harvard University, and an MBA from Massachusetts Institute of Technology in 2014. |
| Becker Hewes |
Becker Hewes is currently the Chief Medical Officer at Blueprint Medicines Corp. He previously worked as the Executive Director-Translational Clinical Oncology at Novartis Institutes for Biomedical Research, Inc. from 2013 to 2017, and as the Chief Medical Officer at Repertoire Immune Medicines, Inc. from 2017 to 2020. Dr. Hewes completed their undergraduate degree at Vanderbilt University and obtained a doctorate degree from Georgetown University School of Medicine. |
| Philina Lee |
Philina Lee is an Independent Director at Fusion Pharmaceuticals, Inc. since 2021. She is also the Chief Commercial Officer at Blueprint Medicines Corp. since 2014. Previously, she worked at Algeta ASA as the Head-US Marketing. Dr. Lee holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of Alberta. |
| Janet Loesberg |
Janet Loesberg is currently the Director at Ambrx, Inc., the Director at All In Together Campaign, Inc., the Independent Director at Ambrx Biopharma Cayman, Inc., the Senior Vice President-Global Medical Affairs at Blueprint Medicines Corp., and the President of The Loesberg Group LLC. She previously served as the Independent Director at Ambrx Biopharma, Inc. and the VP, Head-Portfolio, Project Management & R&D at Janssen Pharmaceuticals, Inc. Dr. Loesberg holds a doctorate degree from the University of Michigan. |
| Anthony L. Boral |
Anthony L. Boral is currently the Executive Vice President-Clinical Development at Blueprint Medicines Corp. Prior to his current position, he worked as the Executive Director-Oncology Clinical Research at Novartis Institutes for Biomedical Research, Inc. from 2010 to 2015, and as the Vice President-Oncology Clinical Research at Millennium Pharmaceuticals, Inc. from 2002 to 2010. Dr. Boral completed his undergraduate degree at Wesleyan University and obtained his doctorate from Albert Einstein College of Medicine, Inc. in 1993. |
| Kathryn Haviland |
Kathryn Haviland is currently the President, Chief Executive Officer & Director at Blueprint Medicines Corp. She is also the Chairman at Fulcrum Therapeutics, Inc. and a Director at Bicara Therapeutics, Inc. Kathryn is a Member of the Harvard Business School Health Industry Alumni Association and the Biopharma Executive Council. In her former positions, Kathryn served as the Executive Director-Commercial Development at PTC Therapeutics, Inc. from 2007 to 2012. She was the Vice President-Rare Diseases at Idera Pharmaceuticals, Inc. from 2014 to 2015, and the Head-Commercial Development at Sarepta Therapeutics, Inc. from 2012 to 2014. Ms. Haviland completed her undergraduate degree at Wesleyan University in 1998. She also holds an MBA from Harvard Business School, which she obtained in 2005. |
| Jeffrey W. Albers |
Mr. Jeffrey W. Albers is an Independent Director at Spyre Therapeutics, Inc., an Independent Chairman at MOMA Therapeutics, Inc., an Independent Director at Kymera Therapeutics, Inc., an Executive Chairman at Blueprint Medicines Corp., a Chairman at Pheon Therapeutics Ltd., a Director-New England Division at American Cancer Society, Inc. and a Venture Partner at Atlas Venture Advisors, Inc. He is on the Board of Directors at Spyre Therapeutics, Inc. and Kymera Therapeutics, Inc. Mr. Albers was previously employed as a President by Algeta ASA, a VP-US Hematology & Oncology Business Unit by Genzyme Corp., an Attorney by Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, and a Vice President-US Hematology & Oncology Business by Sanofi. He also served on the board at Magenta Therapeutics, Inc. He received his undergraduate degree from Indiana University, a graduate degree from Georgetown University and an MBA from Georgetown University. |
| Fouad Namouni |
Fouad Namouni currently works at Blueprint Medicines Corp., as President-Research & Development from 2020. Dr. Namouni also formerly worked at Aprea Therapeutics, Inc., as Independent Director from 2020 to 2022 and Bristol Myers Squibb Co., as Senior VP & Head-Oncology Development from 2016 to 2020. Dr. Namouni received his graduate degree from Université de Paris XI Paris Sud and undergraduate degree from Université de Paris 5 René Descartes. |
| Alexis A. Borisy |
Alexis A. Borisy is the founder of IDRx, Inc. (2021), CombinatoRx, Inc. (2000), FORMA Therapeutics, Inc. (2007), Foundation Medicine, Inc. (2009), Blueprint Medicines Corp. (2008), Relay Therapeutics, Inc. (2015), EQRx International, Inc. (2020), EQRx, Inc. (2019), and ModeX Therapeutics, Inc. (2020). Currently, Mr. Borisy holds the position of Co-Chairman at the Museum of Science, Chairman at Tango Therapeutics, Inc., Lead Independent Director at Revolution Medicines, Inc., Director at Celsius Therapeutics, Inc., and Partner at Third Rock Ventures LLC. Previously, Mr. Borisy held the position of Executive Chairman at Warp Drive Bio, Inc. (2013-2018), Independent Director at Editas Medicine, Inc. (2013-2018), and Independent Director at Magenta Therapeutics, Inc. (2015-2022). Mr. Borisy also has a background in education, having graduated from Harvard University (graduate) and The University of Chicago (undergraduate). |
| Lonnel Coats |
Lonnel Coats is currently the Chief Executive Officer & Director at Lexicon Pharmaceuticals, Inc., an Independent Director at Blueprint Medicines Corp., and an Independent Director at Verve Therapeutics, Inc. He previously served as the President & Chief Executive Officer at Eisai, Inc. from 2010 to 2014, and as the Chief Executive Officer at Eisai Corp. of North America from 2010 to 2014. He also held the position of Director at MGI PHARMA, Inc. in 2008 and Managing Executive Officer at Eisai Co., Ltd. in 2012. Mr. Coats obtained his undergraduate degree from Oakland University (Michigan). |
| Nicholas B. Lydon |
Nicholas B. Lydon was the founder of AnaptysBio, Inc. (founded in 2005) where he served as Director from 2005 to 2010. He was also the founder of Kinetix Pharmaceuticals, Inc. (founded in 1997) where he held the title of President & Chief Executive Officer from 1997 to 2000. In addition, he is the founder of Blueprint Medicines Corp. (founded in 2008) where he currently serves as an Independent Director. He is also the founder of Granite Biopharma LLC (founded in 2003) where he is a Member. Furthermore, he founded Recludix Pharma, Inc. (founded in 2019) and served as Chairman from 2019 to 2022. Dr. Lydon is also the founder of IDRx, Inc... Dr. Lydon's current job is as a Managing Member at Staurus Pharma LLC since 2011. His former positions include being a Director at Ambit Biosciences Corp. from 2004 to 2009, Vice President-Small Molecule Drug Discovery at Amgen, Inc. from 2000 to 2002, and a Principal at Schering-Plough Corp. He also worked as a Principal at Ciba-Geigy AG from 1985 to 1996. Dr. Lydon's education includes an undergraduate degree from the University of Leeds and a doctorate degree from the University Of Dundee. |
| Mark Alan Goldberg |
Mark Alan Goldberg is currently an Independent Director at GlycoMimetics, Inc., a Non-Executive Director at Avacta Group Plc, an Independent Director at Blueprint Medicines Corp., and a Director at Walden Biosciences, Inc. He previously served as an Independent Director at ImmunoGen, Inc., Idera Pharmaceuticals, Inc., and Astellas Gene Therapies, Inc. He was also a Director at aTyr Pharma, Inc., the American Cancer Society, Inc., and the American Cancer Society New England Division, Inc. Goldberg worked as a Senior Vice President-Clinical Research at Genzyme Corp. and as an Executive VP-Global Medical & Regulatory Strategy at Synageva BioPharma Corp. He was also the Chief Medical Officer at CANbridge Life Sciences Ltd. Goldberg holds a doctorate from Harvard Medical School and an undergraduate degree from Harvard College. |
| Daniella Beckman |
Daniella Beckman is currently an Independent Director at Blueprint Medicines Corp. and Vor Biopharma, Inc. She also holds the position of Chief Financial Officer at Tango Therapeutics Sub, Inc. and Tango Therapeutics, Inc. In the past, she served as CFO, Treasurer, Director & Vice President at Idenix Pharmaceuticals LLC from 2011 to 2014. She was also an Independent Director at Translate Bio, Inc. from 2017 to 2021 and at 5:01 Acquisition Corp. from 2020 to 2022. Additionally, she worked as the Chief Financial Officer at BioNTech US, Inc. from 2015 to 2019 and at Beckman Consulting LLC from 2015 to 2019. Ms. Beckman completed her undergraduate degree at Boston University. |
| Habib Joseph Dable |
Habib Joseph Dable's current jobs include Chairman at Aerovate Therapeutics, Inc., Independent Director at Blueprint Medicines Corp., Independent Director at PepGen Inc., and Director at Day One Biopharmaceuticals, Inc. Formerly, Mr. Dable held positions such as President, Chief Executive Officer & Director at Acceleron Pharma, Inc., Director at Biotechnology Innovation Organization, Independent Director at Albireo Pharma, Inc., Independent Director at Millendo Therapeutics, Inc., President-US Pharmaceuticals at Bayer AG, and EVP & Global Head- Specialty Medicine at Bayer HealthCare Pharmaceuticals, Inc. Mr. Dable obtained an undergraduate degree and an MBA from the University of New Brunswick. |
| John Tsai |
John Tsai is currently the Chief Executive Officer at Forcefield Therapeutics Ltd., Chairman & Managing Director at SwanBio Therapeutics, Inc., Independent Director at Blueprint Medicines Corp., and Executive Partner at Syncona Partners LLP. He previously worked as the Director at Novartis Institute for Functional Genomics, Inc., Chief Medical Officer & SVP-Global Medical at Amgen, Inc., Head-Clinical Development at Bristol Myers Squibb Co., and Chief Medical Officer & President at Novartis AG. Dr. Tsai received his undergraduate degree from Washington University in St. Louis and his doctorate from the University of Louisville School of Medicine. |
| Lynn Seely |
Lynn Seely is currently the President, Chief Executive Officer & Director at Lyell Immunopharma, Inc. since 2022. She is also an Independent Director at Blueprint Medicines Corp. since 2016. Previously, she served as the Chief Executive Officer of Myovant Sciences, Inc. from 2019 to 2020 and as the President, Chief Executive Officer & Director of Myovant Sciences Ltd. from 2016 to 2021. Dr. Seely also held positions at Chiron Corp. as an Associate Director-Clinical Development from 1996 to 2000, at Orion Acquisition Corp. II as the Chief Medical Officer in 2005, at Anesiva, Inc. as the Vice President-Clinical Development from 2002 to 2005, at Pro-Duct Health, Inc. as the Vice President-Clinical Development from 2000 to 2001, and at the University of California San Diego as a Faculty Member from 1992 to 1996. She was also the Chief Medical Officer & Senior Vice President at Medivation LLC (California) from 2009 to 2015, the Vice President-Clinical Development at Cytyc Health Corp. from 2001 to 2002, and the Vice President-Clinical Development at Corgentech, Inc. in 2005. Dr. Seely's education includes an undergraduate degree from the University of Oklahoma in 1981 and a doctorate degree from the University of Oklahoma College of Medicine in 1985. |
